Trial · NCT00785122
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
NCT00785122, Phase 1, Phase 2, Completed, Immatics Biotechnologies GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101). Trials, record NCT00785122. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00785122
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
- NCT number
- NCT00785122
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 92 participants, actual
- Lead sponsor
- Immatics Biotechnologies GmbH
- Conditions
- Colorectal Carcinoma
- Interventions
- Endoxana, Leukine, IMA910, Endoxana, Leukine, IMA910, Aldara
- First posted
- 2008-11-05
- Last updated
- 2013-05-16
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease control rate | after 27 weeks of vaccination | |
| Primary | Safety assessment | continuously | Safety assessment with special emphasis on the inclusion of the first 6 patients enrolled according to a pre-specified enrolment plan |
| Secondary | Tumour response rates and SD rate | after 27 and 37 weeks | |
| Secondary | DCR | after 37 weeks on study | |
| Secondary | Duration of response | till End of Study | |
| Secondary | Progression free survival | until tumor progression or death | |
| Secondary | Cellular immunomonitoring | till 27 weeks of vaccination or End Of Study | * T-cell responses to peptides contained in IMA910 * Description of T-cell responses * Percentage of multipeptide responders * Number of TUMAPs to which a response can be detected in multipeptide responders * Other immune cell populations that may influence T-cell responses such as regulatory T cells |
| Secondary | Biomarkers | Pre-Vaccination and End of Study | Pre-vaccination and post-vaccination analysis of serum markers with suspected influence on success of vaccination such as cytokines. |
| Secondary | Analysis of tumor tissue | optional if available | Depending on the amount, type \& quality parameters may be assessed: * Analysis of expression of tumor genes influencing immune response * Presentation of TUMAPs contained in IMA910 * Tumor infiltrating lymphocytes and other immune cell populations * Presence of molecules with suspected influence on immune response * Alteration in the tumor signature under the influence of study treatment with respect to expression of the target genes encoding the TUMAPs contained in IMA910 and all the above mentioned parameters |
| Secondary | Overall Safety | continuously till End of Study |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00785122
GET https://conductscience.org/api/trials/v1/NCT00785122/registered